BIO3 Share Price

Open 18.53 Change Price %
High 19.00 1 Day 0.32 1.72
Low 18.52 1 Week 0.03 0.16
Close 18.88 1 Month 0.75 4.14
Volume 31938 1 Year 5.26 38.62
52 Week High 19.31
52 Week Low 12.02
BIO3 Important Levels
Resistance 2 19.32
Resistance 1 19.14
Pivot 18.80
Support 1 18.62
Support 2 18.44
ETR Germany Most Active Stocks
DBK 15.75 0.13%
DBK 15.75 0.13%
CBK 8.46 1.32%
CBK 8.46 1.32%
EOAN 7.17 0.99%
EOAN 7.17 0.99%
LHA 15.04 3.16%
DTE 16.14 1.13%
DTE 16.14 1.13%
DTE 16.14 1.13%
More..
ETR Germany Top Gainers Stocks
S9H 0.16 45.45%
AYO 0.54 22.73%
5M71 39.00 13.70%
TSE1 1.82 11.66%
E8X 1.00 9.89%
PJXB 4.08 8.80%
LEO 43.76 8.69%
LEO 43.76 8.69%
MF6 4.62 7.44%
BEO 3.38 6.96%
More..
ETR Germany Top Losers Stocks
MPI 0.25 -98.98%
MPI 0.25 -98.98%
APL 2.60 -34.18%
APL 2.60 -34.18%
APL 2.60 -34.18%
FAC 0.25 -16.67%
FAC 0.25 -16.67%
FAC 0.25 -16.67%
ITN 0.34 -15.00%
ZSB 0.10 -9.09%
More..

Biotest AG (ETR: BIO3)

BIO3 Technical Analysis 5
As on 23rd Mar 2017 BIO3 Share Price closed @ 18.88 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 14.38 & Strong Buy for SHORT-TERM with Stoploss of 16.81 we also expect STOCK to react on Following IMPORTANT LEVELS.
BIO3 Target for March
1st Target up-side 18.98
2nd Target up-side 19.94
3rd Target up-side 20.9
1st Target down-side 16.24
2nd Target down-side 15.28
3rd Target down-side 14.32
BIO3 Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.biotest.de
BIO3 Address
BIO3
Landsteinerstrasse 5
Dreieich, 63303
Germany
Phone: 49 6103 801 4406
Fax: 49 6103 801 347
BIO3 Latest News
Interactive Technical Analysis Chart Biotest AG ( BIO3 ETR Germany )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Biotest AG
BIO3 Business Profile
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological medicinal products worldwide. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin for haemophilia A acute therapy and prophylaxis; Haemonine for haemophilia B acute therapy and prophylaxis; Bivigam for primary immune deficiency; Cytotect for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in newborns; Hepatect CP for hepatitis B re-infection prophylaxis; Intratect for primary immune deficiency and secondary antibody deficiency syndromes, as well as autoimmune diseases; Nabi-HB for prophylaxis of hepatitis B virus infection; Varitect CP for zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. The company also provides Albiomin for volume depletion; Biseko for the deficiency of volume and serum proteins; Cofact for the deficiency of clotting factors; Humanalbumin for volume depletion; and Pentaglobin for the treatment of severe bacterial infections. In addition, its products under development include Indatuximab Ravtansine (BT-062) for multiple myeloma and solid tumors; BT-063 for the treatment of systemic lupus erythematosus; BT-094 (Cytotect 70) for the treatment of congenital cytomegalovirus infections; Civacir for the treatment of hepatitis C infection; Tregalizumab (BT-061) for the treatment of rheumatoid arthritis and psoriasis; Fibrinogen for the deficiency of fibrinogen; and IgM concentrate for severe bacterial infections. Biotest Aktiengesellschaft has a collaboration agreement with AbbVie for the development of monoclonal antibody BT-061. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany.